CAIRO - 16 April 2026: The Ministry of Health and Population revealed details of the implementation status of the Vaccine and Biotechnology City, which aims to localize vital industries and enhance health security in Egypt.
Dr. Hossam Abdel Ghaffar, spokesperson for the Ministry of Health and Population, confirmed that the Vaccine City represents one of the most prominent and ambitious national projects, aiming to strengthen Egypt's capabilities in vaccine manufacturing, achieve self-sufficiency, and support exports to regional and international markets.
Construction status
Dr. Abdel Ghaffar explained that construction work on the city, which covers an area of 115,000 square meters and includes 32 buildings and facilities, is progressing well.
The first phase is 100% complete, while the infrastructure is approximately 90% complete.
Dr. Abdel Ghaffar added that the city includes three factories for producing human vaccines and three for veterinary vaccines, in addition to advanced research and development laboratories and a logistics and storage complex, reflecting the massive investments in this vital project.
Targeted production
Dr. Hossam Abdel Ghaffar, the Ministry's official spokesperson, indicated that the targeted production capacity by 2030 is 140 million human doses and 5.5 billion veterinary doses annually.
By 2040, this is expected to rise to 690 million human doses and 11 billion veterinary doses, enabling Egypt to cover approximately 16% of the African continent's needs.
Abdel Ghaffar indicated that the state has developed an ambitious plan to localize vaccine manufacturing, aiming to produce 50% of the country's needs locally by 2030, 75% by 2035, and ultimately achieving complete self-sufficiency by 2040.
He also explained that the project focuses on producing several essential vaccines, such as influenza and polio vaccines, as well as veterinary vaccines, thus supporting both food and health security.
Dr. Abdel Ghaffar emphasized that the project represents a qualitative leap towards self-sufficiency and boosting exports to more than 60 countries, thus strengthening Egypt's position as a leading regional hub for vaccine manufacturing. Discussions also focused on enhancing cooperation with African countries and international partnerships.
He added that the VBC Academy's role lies in serving as a regional center of knowledge in vaccine manufacturing and biotechnology.
The Academy aims to train specialized personnel according to the highest international standards, support scientific research, and link its outputs to industrial applications, while providing advanced infrastructure and integrated training programs that contribute to strengthening national and regional capabilities.
He continued: “This project is a significant strategic step that reflects the state’s commitment to building independent pharmaceutical manufacturing capabilities and enhancing public health at both the local and continental levels.”
Self Sufficiency
Abdel Ghaffar stated that the state aims, through this project, to achieve self-sufficiency in vaccines, reduce reliance on imports, and transform Egypt into a regional hub for vaccine manufacturing and export in Africa and the Middle East.
He added that the project relies on the establishment of an integrated vaccine and biotechnology city, one of the largest projects of its kind in the region.
He also explained that it is being built on an area of approximately 115,000 square meters and includes about 32 diverse facilities.
Abdel-Ghaffar noted that the project is being implemented by specialized national personnel, headed by Dr. Magdy El-Sayed, who is leading the project's executive and technical aspects, in coordination with relevant local and international bodies.
Comments
Leave a Comment